The fusion of targeting moieties with Lamp2b has been used to endow EVs with targeting capacity in several studies, including an αv integrin-targeting iRGD peptide to target tumor cells and tumor-associated vascular endothelium for doxorubicin delivery [150], and a fragment of interleukin 3 (IL3) to target IL3 receptors on chronic myeloid leukemia (CML) cells for delivery of a chemotherapeutic agent or siRNA [151]. The gene discussed is IL3; the disease is neoplasm.